From zero to hero – the rise of Novo Nordisk's best-selling drug

Pharmaceutical giant Novo Nordisk is forever growing, but the drugs that used to drive sales have come and gone over the years. Today, one stands above the rest: quintuple blockbuster Ozempic.

Photo: Tidsvilde Stine/Ritzau Scanpix

In five years, Novo Nordisk has created a multiple blockbuster drug in diabetes treatment Ozempic, which has been center stage in transforming the Danish pharmaceutical firm’s sales.

With an approval falling in December 2017, sales of the drug amounted to literally nothing that year. The year after, sales ”barely” reached DKK 1.8bn (USD 273.4m). In 2021, sales were catapulted to nothing less than DKK 33.7bn (USD 5.1bn). With a threshold of USD 1bn, Ozempic is thus a blockbuster five times over.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs